---

A prospective, post-marketing surveillance (PMS) study to monitor the safety of fixed dose combination of Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg [Recofast Tablets] for the symptomatic relief in patients with upper respiratory tract infections

---

Original Article

Author Details : Sachin Madhukar Kadoo*, Preksha Pramod Patil

Volume : 10, Issue : 1, Year : 2023

Article Page : 37-40

https://doi.org/10.18231/j.ijpp.2023.010

Suggest article by email

Get Permission

---

Abstract

Background: Upper Respiratory Tract Infection (URTI) is the most frequent illness in humans. The vast majority of acute upper respiratory tract infections are caused by viruses. These cause a variety of patient diseases including acute bronchitis, common cold, influenza, and respiratory distress syndromes.
Aim & Objective: The study was conducted in patients with upper respiratory tract infections to see if the medication provides symptomatic relief in these conditions. Other conditions like allergic rhinitis and influenza were also included in the study for symptomatic relief.
Materials and Methods: This is an open label, multicentric, active Post Marketing Surveillance (PMS) study with an objective to assess safety of fixed dose combination regarding Recofast tablets (Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg) which was evaluated in 150 participants from different geographical regions. And then results were documented.
Finding: A total of 19 (13%) patients recorded minor adverse event from these regions. Out of 150 patients 95 were male & 55 were female. All the patients were in the range of 18-80 years.
Results & Conclusion: No significant adverse events were observed during the course of the study, only 13% patients recorded minor adverse events from all regions. Thus this formulation is completely safe and effective in the management of Upper Respiratory Tract Infections and allergies.

Keywords: Upper Respiratory Tract Infection (URTI), Post Marketing Surveillance (PMS), Triprolidine Hydrochloride

How to cite : Kadoo S M, Patil P P, A prospective, post-marketing surveillance (PMS) study to monitor the safety of fixed dose combination of Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg [Recofast Tablets] for the symptomatic relief in patients with upper respiratory tract infections. Indian J Pharm Pharmacol 2023;10(1):37-40

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.